TY - JOUR T1 - Treatment of Patients With Non-small-cell Lung Cancer With Uncommon <em>EGFR</em> Mutations in Clinical Practice JF - Anticancer Research JO - Anticancer Res SP - 5757 LP - 5764 DO - 10.21873/anticanres.14592 VL - 40 IS - 10 AU - YUTAKA YAMADA AU - TOMOHIRO TAMURA AU - YUSUKE YAMAMOTO AU - HIDEO ICHIMURA AU - KENJI HAYASHIHARA AU - TAKEFUMI SAITO AU - HIDEYASU YAMADA AU - TAKEO ENDO AU - RYOTA NAKAMURA AU - YOSHIHISA INAGE AU - HIROAKI SATOH AU - KESATO IGUCHI AU - KAZUTO SAITO AU - MASAHARU INAGAKI AU - NORIHIRO KIKUCHI AU - KOICHI KURISHIMA AU - HIROICHI ISHIKAWA AU - MITSUAKI SAKAI AU - KOICHI KAMIYAMA AU - TOSHIHIRO SHIOZAWA AU - NOBUYUKI HIZAWA AU - IKUO SEKINE AU - YUKIO SATO AU - YASUNORI FUNAYAMA AU - KUNIHIKO MIYAZAKI AU - TAKAHIDE KODAMA AU - SHIGEN HAYASHI AU - AKIHIRO NOMURA AU - HIROYUKI NAKAMURA AU - KINYA FURUKAWA AU - TAKAAKI YAMASHITA AU - HATSUMI OKUBO AU - HISASHI SUZUKI AU - MORIYUKI KIYOSHIMA AU - TAKAYUKI KABURAGI Y1 - 2020/10/01 UR - http://ar.iiarjournals.org/content/40/10/5757.abstract N2 - Background/Aim: To describe real clinical outcomes in patients with non-small cell lung cancer who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials and Methods: We performed a retrospective chart review from 15 medical institutes that cover a population of three million people from April 2008 to March 2019. Results: There were 102 patients with uncommon EGFR mutation. Progression-free survival (PFS) tended to be longer in patients receiving afatinib compared with first-generation EGFR tyrosine kinase inhibitors. PFS in patients treated with afatinib or osimertinib was significantly longer than in patients treated with gefitinib or erlotinib (p=0.030). Multivariate analysis also revealed the contribution of afatinib or osimertinib to increased survival. In patients with exon 20 insertions, chemotherapy was efficacious. Conclusion: In treating patients with uncommon EGFR mutations, our results indicate longer-term survival might be achieved with second-generation or later TKIs and cytotoxic chemotherapeutic drugs. ER -